The BioPharm Brief: Obesity Data and Manufacturing Shape Drug Progress

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, clinical progress, and regulatory strategy. Today’s update focuses on new obesity data, expanded biosimilar manufacturing capacity, a manufacturing-related FDA review delay, and longer-term results for a potential cutaneous lupus treatment.

An investigational dual agonist is showing progress in the increasingly competitive obesity and metabolic disease field. Survodutide met both co-primary endpoints in the phase 3 SYNCHRONIZE-2 trial in adults with overweight or obesity and type 2 diabetes. At 76 weeks, weight loss reached up to 13.1% under the efficacy estimand, compared with 3.1% for placebo, while hemoglobin A1C fell by as much as 1.21 percentage points. However, gastrointestinal adverse events led 18% of treated participants to discontinue therapy, an important consideration as developers compete in the incretin market.

Turning to manufacturing, FDA has approved Alvotech’s second production suite in Reykjavik, Iceland, for commercial US supply of SIMLANDI, its adalimumab biosimilar. The approval allows drug substance manufacturing in either of the company’s 2 suites and doubles the manufacturing capacity available for US supply. It also follows resolution of FDA inspection-related matters at the facility, highlighting the regulatory importance of manufacturing readiness alongside biosimilar development.

That manufacturing theme carries into the next story, in which FDA extended its review of Novo Nordisk’s denecimig for hemophilia A because of ongoing remediation at a manufacturing facility. The agency has not identified deficiencies involving the therapy’s clinical efficacy or safety data, according to the company. Novo continues working with FDA and is targeting a potential US launch in the first half of 2027.

Finally, longer-term data for litifilimab show continued skin improvements through 52 weeks in the AMETHYST study of cutaneous lupus erythematosus. Phase 3 results are expected in the first half of 2027.

Thanks for listening to The BioPharm Brief. For more analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

• Survodutide combines weight-loss and glycemic-control effects in type 2 diabetes, though tolerability remains important.
• Manufacturing capacity and facility remediation continue to influence regulatory timelines.
• Litifilimab shows durable skin responses in a disease with limited targeted treatment options.